Simultaneous HPLC analysis of pseudophedrine hydrochloride,codeine phosphate,and triprolidine hydrochloride in liquid dosage forms

An HPLC method using UV detection is proposed for the simultaneous determination of pseudophedrine hydrochloride, codeine phosphate, and triprolidine hydrochloride in liquid formulation. C18 column (250 mm × 4.0 mm) is used as the stationary phase with a mixture of methanol:acetate buffer:acetonitrile (85:5:10, v/v) as the mobile phase. The factors affecting column separation of the analytes were studied. The calibration graphs exhibited a linear concentration range of 0.06–1.0 mg/ml for pseudophedrine hydrochloride, 0.02–1.0 mg/ml for codeine phosphate, and 0.0025–1.0 mg/ml for triprolidine hydrochloride for a sample size of 5 μl with correlation coefficients of better than 0.999 for all active ingredients studied. The results demonstrate that this method is reliable, reproducible and suitable for routine use with analysis time of less than 4 min.     

Evaluation of new indomethacin dosage forms

Indomethacin, an indole derivative nonsteroidal anti-inflammatory drug, has been available since the early 1960s in gelatin capsules. In 1982, a sustained release product, Indocin SR, was marketed. Awaiting marketing approval is a unique controlled release form of indomethacin, Indos. The disposition of indomethacin includes enterohepatic cycling and extensive metabolism to inactive metabolites. Enterohepatic cycling makes interpretation of bioavailability estimates of indomethacin dosage forms difficult. The relationship of indomethacin plasma concentration to therapeutic effects and side effects is inconclusive. It appears in vivo prostaglandin inhibition occurs at very low plasma concentrations that are achievable with all available dosage forms. Indocin SR is a sustained release capsule of indomethacin designed to deliver 25 mg of drug immediately and 50 mg gradually. Absolute bioavailability of the product is 80%. The plasma concentration-time curves do not show good sustained release characteristics; after four hours plasma concentrations resemble those seen with a single dose of regular capsule. The cost compared with Indocin is competitive. Indos is a zero-order release form of indomethacin. It is a unique drug delivery system that shows good controlled release characteristics. Bioavailability is 85%. Both Indocin SR and Indos are apparently therapeutically equivalent to indomethacin capsules. In elderly patients, Indos has been shown to be associated with fewer side effects than Indocin. Both Indocin SR and Indos have the advantage of once or twice daily dosing.     

High-pressure liquid chromatographic evaluation of aqueous vehicles for preparation of prednisolone and prednisone liquid dosage forms.

A high-pressure liquid chromatographic method was developed that separates prednisolone from prednisone, prednisone from methylprednisolone succinate sodium, and hydrocortisone from hydrocortisone acetate or cortisone acetate. The common liquid dosage preservatives methylparaben, propylparaben, and sodium benzoate do not interfere with quantitative prednisolone, prednisone, and hydrocortisone determinations. The method was used to study prednisolone and prednisone stability in five aqueous vehicles (water, citrate buffer USP, 50% glycerin, 50% sorbitol, and 50% sucrose) containing 10% (v/v) ethanol. Prednisone crystallized out in all vehicles except glycerin, in which it appeared to be stable for at least 92 days. Prednisolone did not crystallize in any vehicle but decomposed quickly in citrate buffer. Sorbitol and glycerin appeared to be the best vehicles for prednisolone. The developed method was applied successfully to the quantitative determinations of prednisolone, prednisone, and hydrocortisone in commercial tablets.     

GLC determination of trihexyphenidyl hydrochloride dosage forms.

A rapid, sensitive, and specific GLC method for the quantitation of trihexyphenidyl hydrochloride in various pharmaceutical dosage forms is described. The procedure involves chloroform extraction of the active ingredient from a weakly acidic solution, followed by GLC determination using a 3% methyl silicone column. The specificity of the system in relation to several compendial drug analogs also is reported.     

Stability of dry coated solid dosage forms

The dry coating process was evaluated in terms of storage stability investigating drug release and agglomeration tendency of the different coated oral dosage forms; hydroxypropyl methylcellulose acetate succinate (HPMCAS) was used with triethylcitrate (TEC) as plasticizer and acetylated monoglyceride (Myvacet^®) as wetting agent. Talc or colloidal silicon dioxide (Aerosil^®) was used as anti-tacking agents. In contrast to coating formulations consisting of HPMCAS and Myvacet^® all formulations containing TEC showed enteric resistance and no agglomeration tendency after preparation. After storage at 10% RH?±?5% enteric resistance is increased slightly. This increase is more pronounced at 60% RH?±?5%. The formulations without anti-tacking agents showed higher drug releases after 12 and 24 months due to the damage of the film’s integrity during sample preparation caused by the high tackiness of the film. Tackiness is not affected by storing if samples are stored at low relative humidity. At high relative humidity tackiness increases upon storage especially for formulations without anti-tacking agents. The sieving results of the agglomeration measurements after storage can be confirmed by ring shear measurements performed immediately after preparation and approved to be a tool, which is able to predict the agglomeration during storage.     

Rapid fluorometric determination of procainamide hydrochloride dosage forms.

A fluorometric procedure for procainamide hydrochloride was developed, and it offers improvements in ease, speed, and sensitivity over the official method. The new procedure is based on the reaction with fluorescamine in aqueous medium at pH 7.5 to form a fluorophore, with activation and emission wavelengths of 400 and 485 nm, respectively. The fluorescence is linear (r = 0.999) over the 0. 04-1 mug/ml concentration range and is stable for at least 2 hr. Recovery data appeared to be accurate, quantitative, and reproducible. The overall recovery was 99.8% with a standard deviation of +/-1.14 (n = 5). The method was successfully applied to commercially available dosage forms.     

Rapid, stability-indicating, high-pressure liquid chromatographic determination of theophylline, guaifenesin, and benzoic acid in liquid and solid pharmaceutical dosage forms.

Theophylline, guaifenesin, and benzoic acid were determined by reversed-phase high-pressure liquid chromatography without interference from active and/or vehicle decomposition. A degradation product of sucrose, 5-hydroxymethylfurfural, can be identified and quantified in liquid samples simultaneously.     

Stability of polymorphic forms of ranitidine hydrochloride

Ranitidine-HCl can exist in two different polymorphic forms: form I (m.p. 134-140 degrees C) and form II (m.p. 140-144 degrees C). In the present study the stability of form I of ranitidine-HCl to a selection of powder pretreatments, to reflect conditions which might occur in manufacturing procedures, and also to a limited range of storage conditions was investigated. The original samples of form I and form II used were characterised by X-ray powder diffraction (XRPD), hot stage microscopy (HSM) and differential scanning calorimetry (DSC). A quantitative XRPD method for determining the fraction of form II in the presence of form I was used. XRPD data were analysed using regression techniques and artificial neural networks (ANN). The quantitative XRPD technique was then used to monitor the relative proportion of form II in each treated sample. Pretreatments of form I included (i) mixing with form II or with common excipients (ii) compression and grinding (iii) contact with solvents (followed by drying) before storage. Storage conditions involved three temperatures (20 degrees C, 30 degrees C, 42 degrees C) and three relative humidities (45% RH; 55% RH; 75% RH). Samples were stored for a period of 6 months. A limited factorial design was used. No increase in the form II:form I ratio was observed in the following pretreatment processes: introduction of form II nuclei into form I; introduction of excipients to form I; compression of form I powder at 5 and 15 tons; normal mixing and grinding processes; addition of isopropanol (IPA) or water/IPA mix followed by drying. In the pretreatment process where water was added to form I powder (with most or all of the powder dissolving), drying of the liquefied mass led to a mix of form I and form II. On storage at room temperature (20-30 degrees C), low relative humidity (45-55% RH), and in an air-tight container there was no increase in the form II:form I ratio. Storage of form I/form II mixes, particularly at high humidity, resulted in a preferential loss of form II (compared to form I). Loss was greater at 30 degrees C/75% RH than at 20 degrees C/75% RH. Form II was also preferentially lost under low humidity conditions created by a saturated solution of potassium carbonate (45% RH) at the elevated temperature of 42 degrees C. This environment was shown to be acidic.     

Development of oral liquid dosage forms of acetazolamide

Two oral liquid dosage forms of acetazolamide have been developed. Using the solubility profiles, polyethylene glycol 400 (7%, v/v) was used as the solubilizing agent and propylene glycol (53%, v/v) as the cosolvent to keep acetazolamide in solution. Because of the bitter taste of acetazolamide, sweetening agents (simple syrup, sorbitol solution, and artificial sweeteners) and flavors (raspberry, sweet, and menthol) were added to the final formulations. A buffer (either phosphate or citrate) solution was used to maintain a pH value of 4 (pH of maximum stability as reported earlier) to minimize hydrolysis. The final dosage forms were stable for at least 90 days at 37 degrees C (loss of potency of 5%). According to FDA guidelines, a tentative expiry date of 2 years at 25 degrees C is justifiable.     

不同固体剂型盐酸伐昔洛韦制剂的溶出度考查

目的：比较4个不同厂家固体制剂盐酸伐昔洛韦片剂和胶囊的溶出度,为临床用药提供参考。方法：采用紫外分光光度法测定盐酸伐昔洛韦含量,转篮法测定溶出度,并以威布尔分布模型拟合溶出参数,再对T50,Td,m进行统计分析。结果：4个厂家不同固体剂型中盐酸伐昔洛韦片剂和胶囊剂的溶出度均符合2005年版《中国药典》规定,其T50、Td、m值两两间均存在显著性差（P（0.05）。结论：该方法操作简便、准确,可用于该药溶出度的测定。     

Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms

The pharmacokinetics of completely metabolized papaverine hydrochloride were characterized by a linear sum of three exponentials on intravenous administration with respective 1.5, 19 and 107 min apparent half lives. There was a time-dependent partition from plasma water into red blood cells with an apparent half life of 1.5--3 min. The partition coefficient normally ranged between 8 and 15 at therapeutic levels but approached unity at high plasma concentrations to indicate a saturable partition. Apparent compartmental volumes of distribution referenced to total concentrations in the plasma were 4.3--4.8, 11--13 and 20--25 liters. Protein binding was 91--95%. The hepatic clearance of blood was 960 ml/min, corresponding to a hepatic efficiency of 69%, and indicated that the clearance of protein-bound drug was consistent with the observed first pass metabolism of 70% for oral solutions. No dose dependency was observed on intravenous administration or on oral administration of solutions and tablets. Tablets with release lag times of 10--15 min showed relative bioavailabilities of 52%. Two different lots of sustained release capsules showed 68 and 89% relative bioavailabilities. Release lag times among capsules ranged between 0 and 170 min. Loo-Riegelman calculations and analog computer fittings were consistent with a half life of absorption from oral solutions of 19 min and zero order release rates from tablets and sustained release capsules. Chronic studies of tablets q.i.d. and capsules b.i.d. confirmed lack of accumulation. An appropriately designed 300 mg sustained release capsule, b.i.d., for an arbitrary plasma level of 0.200 microgram/ml should have one tenth the release rate of the studied capsules.     

Papaverine hydrochloride: the evaluation of two new dosage forms.

The bioavailability of papaverine, administered as sustained release capsules, an elixir, and soft gelatin capsules, was studied with volunteers. Blood samples were assayed for papaverine, using a gas chromatographic method, following the administration of single 150 mg doses of papaverine HC1. The elixir and the soft gelatin capsule resulted in nearly identical papaverine blood levels, while peak levels, area under the blood level-time curve, and plasma levels 0.5, 1.0, 1.5, and 2.0 hours after dosing with the sustained release capsule were significantly (p less than 0.01) lower.     

Assay of lercanidipine hydrochloride in dosage forms using nucleophilic substitution reaction

A simple and sensitive spectrophotometric method has been developed for the assay of lercanidipine hydrochloride (LER) in bulk and in formulations. The method is based on the formation of coloured species between the drug and 1,2-naphthaquinone-4-sulphonic acid sodium salt (NQS) by means of nucleophilic substitution reaction. Absorbance was measured at λ(max) = 460 nm. The method was analyzed statistically. The system obeyed the Beer's law in the range 20-100 μg mL?1. Molar absorptivity value was found to be 4.79 × 103 L mol?1 cm?1. Limits of detection and quantification were found to be as low as 0.04 and 0.13 μg mL?1. Precision (RSD, 0.4%) and accuracy (recovery 99.2 ± 0.6 to 101.1 ± 0.8%) of the developed method were evaluated.     

Stabilized normal-phase high-performance liquid chromatographic analysis of aspirin and salicylic acid in solid pharmaceutical dosage forms

A simultaneous analysis of aspirin and nonaspirin salicylates in solid pharmaceutical dosage forms is described. Two separate extraction procedures are employed, one for plain aspirin tablets and one for tablets containing aspirin plus buffers or antacids. The analyses of the extracted samples are accomplished by a stabilized normal-phase high-performance liquid chromatographic (HPLC) procedure. Prepared samples and standards are stable for up to 24 h, and the methodology is suitable for an automated HPLC system.